BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 1192353)

  • 1. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
    Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
    JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences.
    Geskin LJ; Angello JT; Bagot M; Guenova E; Nikbakht N; Querfeld C; Scarisbrick JJ
    Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):40-47. PubMed ID: 37802679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gelling Your Dermatology Nursing Practice: A Practical Guide for Managing the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel.
    McCann SA; Chase AB; Tawa MC
    J Dermatol Nurses Assoc; 2016 May; 8(3):180-192. PubMed ID: 28529678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study.
    Bazewicz C; Verardi N; Akilov O
    Oncologist; 2024 Mar; 29(3):272-274. PubMed ID: 38243388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Line-field confocal optical coherence tomography: A new in vivo assessment tool for cutaneous mycosis fungoides.
    Soglia S; Pérez-Anker J; Ghini I; Lenoir C; Maione V; Sala R; Tonon F; Suppa M; Calzavara-Pinton PG; Malvehy J; Venturini M
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):e296-e298. PubMed ID: 37983937
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
    Liner K; Brown C; McGirt LY
    Drug Des Devel Ther; 2018; 12():241-254. PubMed ID: 29440874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma.
    Van Scott EJ; Grekin DA; Kalmanson JD; Vonderheid EC; Barry WE
    Cancer; 1975 Nov; 36(5):1613-8. PubMed ID: 1192353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group.
    Molin L; Thomsen K; Volden G
    Acta Derm Venereol; 1979; 59(1):64-8. PubMed ID: 84470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance.
    Van Scott EJ; Kalmanson JD
    Cancer; 1973 Jul; 32(1):18-30. PubMed ID: 4577503
    [No Abstract]   [Full Text] [Related]  

  • 11. Topical nitrogen mustard in mycosis fungoides.
    Zachariae H
    Int J Clin Pharmacol Res; 1985; 5(3):193-8. PubMed ID: 4018954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical chemotherapy of mycosis fungoides.
    Grekin DA; Zackheim HS; Epstein EH
    Cutis; 1979 Nov; 24(5):543-6. PubMed ID: 520032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete regressions of mycosis fungoides with topical mechlorethamine hydrochloride.
    Van Scott EJ
    JAMA; 1972 Nov; 222(9):1172. PubMed ID: 4678061
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.